proqr.com (PRQR) - Enterprise Value to EBITDA Ratio
The development of treatments for hereditary kidney and vision pathologies is insulated from inflation, relying instead on scientific advancements. ProQR Therapeutics N.V. (PRQR) revenues are fueled by upfront payments from major partners for access to RNA editing technologies. This daily price chart, with an EV/EBITDA metric of 0.00, visualizes the business valuation. Meanwhile, ProQR Therapeutics N.V. (PRQR) minimizes capital expenditures by utilizing external certified facilities to scale drug production.
PRQR (proqr.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization indicators:
- business book valuation details:
- debt and solvency information:
- net income and valuation multiples indicators:
PRQR - Company Net Income|Future Profit ProQR Therapeutics N.V.|PRQR - P/E Multiple|Projected Price to Earnings ProQR Therapeutics|PRQR - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple PRQR|PRQR - Operating income before deduction of amortization|Net earnings per share (EPS TTM) ProQR Therapeutics N.V.|PRQR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months proqr.com|PRQR - Expected net earnings per share growth this year|Expected earnings per share growth for next year ProQR Therapeutics N.V.
Summary company analysis:ProQR Therapeutics NV PRQR
ProQR Therapeutics N.V. (PRQR) maintains stability through the automation of RNA synthesis via the implementation of high-precision robotic systems. This indicator compares the total enterprise value with operating profit before depreciation, taxes, and interest, neutralizing the impact of accounting policies. It is critical for investors to distinguish market volatility from fundamental shifts in 10-K filings. The EV/EBITDA ratio dynamics, accounting for capital structure, allow for an objective valuation of assets during this period of technological expansion.
Competitors of ProQR Therapeutics N.V.
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Business Value to Operating Income Before Depreciation QGEN|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRSP: Enterprise Value to Operating Income Before Depreciation Ratio|WGS (Sema4) - EV/EBITDA Multiple|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|SRPT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|Business Value to Operating Income Before Depreciation TXG|Intellia - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio WVE (wavelifesciences.com)|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Sionna Therapeutics, Inc. SION|Enterprise Value to EBITDA Ratio PRME (Prime Medicine Corp)|EV/EBITDA Multiple Taysha Corp (TSHA)|uniQure N.V. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MGTX (meiragtx.com)|REGENXBIO - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Solid Biosciences Inc SLDB|OCGN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio PacBio Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Benitec Biopharma Inc.|designtx.com (DSGN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio RCKT (Rocket Pharmaceuticals, Inc.)|FDMT (4DMT) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|KRRO: Enterprise Value to Operating Income Before Depreciation|EDIT: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio silence-therapeutics.com SLN|CDXS (codexis.com) - Enterprise Value to EBITDA Ratio|SGMO (Sangamo Therapeutics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAUT|Metagenomi Therapeutics (MGX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|GBIO: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio BOLD|Business Value to Operating Income Before Depreciation XCUR|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple Phio Pharmaceuticals (PHIO)|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TransCode Therapeutics, Inc. - Business Value to Operating Income Before Depreciation|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluebird Bio (BLUE)|immunoprecise.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMGA (Omega Therapeutics)|EV/EBITDA Multiple singulargenomics.com OMIC|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SYRS|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRACON Pharmaceuticals, Inc - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
